$NRXP
NRX Pharmaceuticals, Inc.

2023 Q3 Form 10-Q Financial Statement

#000155837023014873 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.494M $4.065M
YoY Change -50.24% -38.8%
% of Gross Profit
Research & Development $3.314M $3.873M
YoY Change -19.74% 30.93%
% of Gross Profit
Depreciation & Amortization $4.000K $1.000K
YoY Change 300.0% 0.0%
% of Gross Profit
Operating Expenses $5.808M $8.188M
YoY Change -36.46% -14.71%
Operating Profit -$5.808M -$8.188M
YoY Change -36.46% -14.71%
Interest Expense $40.00K $145.0K
YoY Change -31.03% 4.32%
% of Operating Profit
Other Income/Expense, Net -$254.0K -$529.0K
YoY Change -537.93% -120.21%
Pretax Income -$6.062M -$8.717M
YoY Change -33.26% 24.85%
Income Tax
% Of Pretax Income
Net Earnings -$6.062M -$8.717M
YoY Change -33.26% 24.85%
Net Earnings / Revenue
Basic Earnings Per Share -$0.07 -$0.12
Diluted Earnings Per Share -$0.07 -$0.12
COMMON SHARES
Basic Shares Outstanding 81.70M 70.31M
Diluted Shares Outstanding 81.95M 73.22M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.902M $14.97M
YoY Change -51.22% -39.02%
Cash & Equivalents $8.902M $14.97M
Short-Term Investments
Other Short-Term Assets $4.187M $4.819M
YoY Change -36.1% -38.74%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $13.09M $19.79M
YoY Change -47.22% -38.95%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $21.00K $21.00K
YoY Change -8.7% 10.53%
Total Long-Term Assets $21.00K $21.00K
YoY Change -8.7% 10.53%
TOTAL ASSETS
Total Short-Term Assets $13.09M $19.79M
Total Long-Term Assets $21.00K $21.00K
Total Assets $13.11M $19.81M
YoY Change -47.19% -38.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.631M $2.205M
YoY Change 67.48% -28.36%
Accrued Expenses $4.728M $5.783M
YoY Change -6.69% 73.87%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $10.07M $12.69M
YoY Change
Total Short-Term Liabilities $19.33M $22.62M
YoY Change 140.33% 219.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $19.33M $22.62M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $19.33M $22.62M
YoY Change 140.33% 219.4%
SHAREHOLDERS EQUITY
Retained Earnings -$248.8M -$242.8M
YoY Change 16.95% 19.19%
Common Stock $84.00K $80.00K
YoY Change 23.53% 19.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.217M -$2.808M
YoY Change
Total Liabilities & Shareholders Equity $13.11M $19.81M
YoY Change -47.19% -38.92%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$6.062M -$8.717M
YoY Change -33.26% 24.85%
Depreciation, Depletion And Amortization $4.000K $1.000K
YoY Change 300.0% 0.0%
Cash From Operating Activities -$4.565M -$7.812M
YoY Change -27.15% -47.18%
INVESTING ACTIVITIES
Capital Expenditures $4.000K -$2.000K
YoY Change -180.0% -33.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$4.000K $2.000K
YoY Change -20.0% -166.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.503M 6.273M
YoY Change 5267.86% -829.42%
NET CHANGE
Cash From Operating Activities -4.565M -7.812M
Cash From Investing Activities -4.000K 2.000K
Cash From Financing Activities -1.503M 6.273M
Net Change In Cash -6.072M -1.537M
YoY Change -3.6% -90.18%
FREE CASH FLOW
Cash From Operating Activities -$4.565M -$7.812M
Capital Expenditures $4.000K -$2.000K
Free Cash Flow -$4.569M -$7.810M
YoY Change -27.02% -47.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73221563
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65732343
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70260622
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64348966
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
80388330
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66442989
dei Entity Registrant Name
EntityRegistrantName
NRX Pharmaceuticals, Inc.
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Entity Central Index Key
EntityCentralIndexKey
0001719406
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38302
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2844431
dei Entity Address Address Line1
EntityAddressAddressLine1
1201 Orange Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
dei Entity Address City Or Town
EntityAddressCityOrTown
Wilmington
dei Entity Address State Or Province
EntityAddressStateOrProvince
DE
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19801
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
254-6134
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
81700918
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14969000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20054000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4819000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5741000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
19788000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
25795000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21000
CY2023Q2 us-gaap Assets
Assets
19809000
CY2022Q4 us-gaap Assets
Assets
25816000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2205000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2076000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5783000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4855000
CY2023Q2 nrxp Accrued Clinical Site Costs
AccruedClinicalSiteCosts
1115000
CY2022Q4 nrxp Accrued Clinical Site Costs
AccruedClinicalSiteCosts
914000
CY2023Q2 nrxp Convertible Notes Payable Accrued Interest
ConvertibleNotesPayableAccruedInterest
12692000
CY2022Q4 nrxp Convertible Notes Payable Accrued Interest
ConvertibleNotesPayableAccruedInterest
7703000
CY2023Q2 nrxp Insurance Loan Payable
InsuranceLoanPayable
786000
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
36000
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
37000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
22617000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15585000
CY2022Q4 nrxp Notes Payable And Accrued Interest Non Current
NotesPayableAndAccruedInterestNonCurrent
2822000
CY2023Q2 us-gaap Liabilities
Liabilities
22617000
CY2022Q4 us-gaap Liabilities
Liabilities
18407000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
80388330
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
66442989
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
80000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
67000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
239887000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
230339000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-22000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-242753000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-222997000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2808000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7409000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19809000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25816000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3873000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2958000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7523000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8441000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4065000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6642000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9850000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16864000
CY2023Q2 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
250000
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
250000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
8188000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
9600000
us-gaap Operating Expenses
OperatingExpenses
17623000
us-gaap Operating Expenses
OperatingExpenses
25305000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8188000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9600000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17623000
us-gaap Operating Income Loss
OperatingIncomeLoss
-25305000
CY2023Q2 us-gaap Interest Income Other
InterestIncomeOther
145000
CY2022Q2 us-gaap Interest Income Other
InterestIncomeOther
23000
us-gaap Interest Income Other
InterestIncomeOther
301000
us-gaap Interest Income Other
InterestIncomeOther
23000
us-gaap Interest Expense
InterestExpense
3000
CY2023Q2 nrxp Increase Decrease In Fair Value Of Convertible Debt
IncreaseDecreaseInFairValueOfConvertibleDebt
-663000
nrxp Increase Decrease In Fair Value Of Convertible Debt
IncreaseDecreaseInFairValueOfConvertibleDebt
-2435000
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-11000
CY2022Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
116000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
273000
CY2022Q2 nrxp Gain Loss On Fair Value Of Cash Earnout Liability
GainLossOnFairValueOfCashEarnoutLiability
2479000
nrxp Gain Loss On Fair Value Of Cash Earnout Liability
GainLossOnFairValueOfCashEarnoutLiability
4582000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-529000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2618000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2133000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4875000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8717000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-6982000
us-gaap Net Income Loss
NetIncomeLoss
-19756000
us-gaap Net Income Loss
NetIncomeLoss
-20430000
CY2023Q2 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option Reclassification Adjustment From Aoci For Derecognition After Tax
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax
128000
us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option Reclassification Adjustment From Aoci For Derecognition After Tax
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax
22000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-128000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-22000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-8845000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-6982000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-19778000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-20430000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73221563
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65732343
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70260622
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64348966
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7409000
CY2023Q1 nrxp Sale Of Stock And Warrants Issuance Costs
SaleOfStockAndWarrantsIssuanceCosts
351000
CY2023Q1 nrxp Common Stock And Warrants Issued In Private Placement Net Of Issuance Costs
CommonStockAndWarrantsIssuedInPrivatePlacementNetOfIssuanceCosts
2545000
CY2023Q1 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option Reclassification Adjustment From Aoci For Derecognition After Tax
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax
-106000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
695000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11039000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-284000
CY2023Q2 nrxp Sale Of Stock And Warrants Issuance Costs
SaleOfStockAndWarrantsIssuanceCosts
2168000
CY2023Q2 nrxp Common Stock And Warrants Issued In Private Placement Net Of Issuance Costs
CommonStockAndWarrantsIssuedInPrivatePlacementNetOfIssuanceCosts
5577000
CY2023Q2 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option Reclassification Adjustment From Aoci For Derecognition After Tax
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionReclassificationAdjustmentFromAociForDerecognitionAfterTax
128000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
544000
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
200000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8717000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2808000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
20806000
nrxp Sale Of Stock And Warrants Issuance Costs
SaleOfStockAndWarrantsIssuanceCosts
2020000
CY2022Q1 nrxp Common Stock And Warrants Issued In Private Placement Net Of Issuance Costs
CommonStockAndWarrantsIssuedInPrivatePlacementNetOfIssuanceCosts
22980000
CY2022Q1 nrxp Stock Issued For Payment Of Consulting Services
StockIssuedForPaymentOfConsultingServices
17000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1334000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-13448000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
31689000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
342000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
987000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-6982000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
25352000
us-gaap Profit Loss
ProfitLoss
-19756000
us-gaap Profit Loss
ProfitLoss
-20430000
us-gaap Depreciation
Depreciation
2000
us-gaap Depreciation
Depreciation
2000
us-gaap Share Based Compensation
ShareBasedCompensation
1239000
us-gaap Share Based Compensation
ShareBasedCompensation
2321000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-273000
nrxp Gain Loss On Fair Value Of Cash Earnout Liability
GainLossOnFairValueOfCashEarnoutLiability
4582000
nrxp Increase Decrease In Fair Value Of Convertible Debt
IncreaseDecreaseInFairValueOfConvertibleDebt
-2435000
nrxp Noncash Settlement Expense
NoncashSettlementExpense
250000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-922000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2757000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
129000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-609000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
879000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1157000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13901000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25171000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
2000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
6000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-518000
nrxp Repayments Of Convertible Note
RepaymentsOfConvertibleNote
90000
nrxp Proceeds From Issuance Of Insurance Loan
ProceedsFromIssuanceOfInsuranceLoan
786000
nrxp Net Proceeds From Payments For Issuance Of Common Stock And Warrants In Private Placement Net Of Issuance Costs
NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts
8122000
nrxp Net Proceeds From Payments For Issuance Of Common Stock And Warrants In Private Placement Net Of Issuance Costs
NetProceedsFromPaymentsForIssuanceOfCommonStockAndWarrantsInPrivatePlacementNetOfIssuanceCosts
22638000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8818000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
22120000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5085000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3057000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20054000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27605000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14969000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24548000
us-gaap Interest Paid Net
InterestPaidNet
205000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
200000
nrxp Issuance Of Common Stock Warrants As Offering Costs
IssuanceOfCommonStockWarrantsAsOfferingCosts
75000
nrxp Issuance Of Common Stock Warrants As Offering Costs
IssuanceOfCommonStockWarrantsAsOfferingCosts
726000
us-gaap Stock Issued1
StockIssued1
17000
CY2023Q1 nrxp Number Of Patients Reviewed
NumberOfPatientsReviewed
50
CY2023Q1 nrxp Percentage Of Standard Set For Veteran Rating Team And Site Raters
PercentageOfStandardSetForVeteranRatingTeamAndSiteRaters
0.90
CY2023Q1 nrxp Percentage Of Threshold Congruence Achieved
PercentageOfThresholdCongruenceAchieved
0.94
CY2023Q2 nrxp Threshold Number Of States Covered Under Recruitment Campaign
ThresholdNumberOfStatesCoveredUnderRecruitmentCampaign
45
CY2023Q1 nrxp Minimum Shelf Life Of Supplies
MinimumShelfLifeOfSupplies
P2Y
nrxp Threshold Number Of Patients Data Enough To Demonstrate Preliminary Safety And Efficacy
ThresholdNumberOfPatientsDataEnoughToDemonstratePreliminarySafetyAndEfficacy
200
nrxp Number Of Patients In Randomized Prospective Trial
NumberOfPatientsInRandomizedProspectiveTrial
200
CY2023Q2 us-gaap Cash
Cash
15000000.0
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
12692000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in its financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the convertible note payable, earnout cash liability, stock options, warrants, and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk and Off-Balance Sheet Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are occasionally invested in certificates of deposit. The Company maintains each of its cash balances with high-quality and accredited financial institutions and accordingly, such funds are not exposed to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Deposits in financial institutions may, from time to time, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy.  </p>
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
nrxp Share Based Compensation Arrangement Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
46000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1956237
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
3.71
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y7M6D
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
2018000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1966000
CY2023Q2 nrxp Prepaid Clinical Development Expenses
PrepaidClinicalDevelopmentExpenses
1901000
CY2022Q4 nrxp Prepaid Clinical Development Expenses
PrepaidClinicalDevelopmentExpenses
3167000
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
735000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
331000
CY2023Q2 nrxp Prepaid Legal Expenses
PrepaidLegalExpenses
159000
CY2022Q4 nrxp Prepaid Legal Expenses
PrepaidLegalExpenses
270000
CY2023Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
6000
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
7000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4819000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5741000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2548849
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.32
CY2023Q2 nrxp Other Accrued Expenses Current
OtherAccruedExpensesCurrent
2856000
CY2022Q4 nrxp Other Accrued Expenses Current
OtherAccruedExpensesCurrent
2616000
CY2023Q2 nrxp Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1183000
CY2022Q4 nrxp Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
923000
CY2023Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
949000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
974000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
795000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
342000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5783000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4855000
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
11020000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
497000
CY2023Q2 nrxp Debt Instrument Repayments Of Principal
DebtInstrumentRepaymentsOfPrincipal
288000
CY2023Q2 nrxp Long Term Debt Before Fair Value Adjustments
LongTermDebtBeforeFairValueAdjustments
10235000
nrxp Increase Decrease In Fair Value Of Convertible Debt
IncreaseDecreaseInFairValueOfConvertibleDebt
-2435000
nrxp Increase Decrease In Fair Value Accumulated Other Comprehensive Income
IncreaseDecreaseInFairValueAccumulatedOtherComprehensiveIncome
22000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
12692000
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
16484923
CY2022 nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term2
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm2
P3Y7M2D
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.49
CY2023Q1 nrxp Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
3866666
CY2023Q1 nrxp Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
P4Y8M8D
CY2023Q1 nrxp Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued
0.75
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
20351589
CY2023Q1 nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term2
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm2
P3Y7M24D
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.40
CY2023Q2 nrxp Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
9670002
CY2023Q2 nrxp Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
P4Y11M8D
CY2023Q2 nrxp Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssued
0.65
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
30021591
CY2023Q2 nrxp Class Of Warrant Or Right Weighted Average Remaining Contractual Term2
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm2
P4Y4M9D
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.51
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2548849
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.32
CY2022 nrxp Share Based Compensation Arrangement Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
618000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2548849
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.32
CY2023Q1 nrxp Share Based Compensation Arrangement Options Outstanding Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
124000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
46000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1100000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y10M24D
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
544000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
987000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1239000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2321000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q4 nrxp Minimum Equity Value Required For Transfer Of Assets
MinimumEquityValueRequiredForTransferOfAssets
50000000
CY2022Q4 nrxp Minimum Equity Required For Transfer Of Assets From Related Party Number Of Consecutive Trading Days
MinimumEquityRequiredForTransferOfAssetsFromRelatedPartyNumberOfConsecutiveTradingDays
20
CY2022Q4 nrxp Minimum Equity Required For Transfer Of Assets From Related Party Number Of Trading Days
MinimumEquityRequiredForTransferOfAssetsFromRelatedPartyNumberOfTradingDays
20
CY2023Q2 nrxp License Agreement Threshold Aggregate Liquidity
LicenseAgreementThresholdAggregateLiquidity
600000
CY2023Q2 nrxp Related Party Transaction Consulting Fee Payable Per Month
RelatedPartyTransactionConsultingFeePayablePerMonth
100000
CY2023Q2 nrxp Related Party Transactions Performance Based Annual Bonus Minimum Target
RelatedPartyTransactionsPerformanceBasedAnnualBonusMinimumTarget
300000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001558370-23-014873-index-headers.html Edgar Link pending
0001558370-23-014873-index.html Edgar Link pending
0001558370-23-014873.txt Edgar Link pending
0001558370-23-014873-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nrxp-20230630.xsd Edgar Link pending
nrxp-20230630x10q.htm Edgar Link pending
nrxp-20230630xex10d1.htm Edgar Link pending
nrxp-20230630xex31d1.htm Edgar Link pending
nrxp-20230630xex31d2.htm Edgar Link pending
nrxp-20230630xex32d1.htm Edgar Link pending
nrxp-20230630xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
nrxp-20230630_cal.xml Edgar Link unprocessable
nrxp-20230630_def.xml Edgar Link unprocessable
nrxp-20230630_lab.xml Edgar Link unprocessable
nrxp-20230630_pre.xml Edgar Link unprocessable
nrxp-20230630x10q_htm.xml Edgar Link completed
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending